BioLife Solutions, Inc. (NASDAQ:BLFS) Receives $29.43 Consensus PT from Analysts

BioLife Solutions, Inc. (NASDAQ:BLFS) has received a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $29.43.

A number of research firms have commented on BLFS. Craig Hallum increased their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. TD Cowen lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. KeyCorp boosted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Northland Securities lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Finally, Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Aby J. Mathew sold 7,604 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. The trade was a 2.68 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,678 shares of company stock worth $317,990. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of BioLife Solutions by 13.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock worth $1,835,000 after acquiring an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BioLife Solutions in the fourth quarter worth approximately $31,000. Point72 Asset Management L.P. bought a new position in BioLife Solutions during the 4th quarter valued at $11,113,000. ProShare Advisors LLC bought a new position in BioLife Solutions during the 4th quarter valued at $282,000. Finally, Millennium Management LLC increased its position in shares of BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after purchasing an additional 377,111 shares during the period. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $28.32 on Wednesday. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -26.72 and a beta of 1.91. BioLife Solutions has a one year low of $14.50 and a one year high of $29.55. The company’s 50-day simple moving average is $26.88 and its 200-day simple moving average is $25.41. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.